share_log

Morgan Stanley Maintains Overweight on Cerevel Therapeutics Hldg, Lowers Price Target to $38

Benzinga ·  Nov 2, 2023 12:11

Morgan Stanley analyst Matthew Harrison maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight and lowers the price target from $42 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment